
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is experiencing robust growth across its core business segments, with liver disease franchise sales rising 9% year-over-year to $3 billion, propelled by the successful launch of Livdelzi in primary biliary cholangitis. The company's total HIV sales reached $19.6 billion, marking a 16% year-over-year increase, driven by strong demand, higher average realized prices, and favorable inventory dynamics, with Descovy alone achieving sales of $616 million—21% higher than the previous year. Additionally, Gilead's oncology segment is expanding, with a 12% increase in sales year-over-year, contributing to a solid performance across its diverse portfolio amid a competitive landscape.
Bears say
Gilead Sciences is facing significant revenue challenges as it anticipates a continued decline in Veklury sales due to decreasing COVID-19 hospitalizations, alongside expectations of a mid-teen percentage drop in HIV revenue for the upcoming fiscal year. Additionally, the company is navigating competitive pressures in both the HIV and oncology sectors, with concerns regarding the performance of its next-generation treatments and CAR-T therapies, which are crucial for its growth strategy. Although Gilead expects to see operating margin expansion through stable R&D costs and reduced SG&A expenses, the overall revenue trends and competitive landscape present substantial risks to its financial outlook.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares